The need to tailor the omission of axillary lymph node dissection to patients with good prognosis and sentinel node micro-metastases.
Fiche publication
Date publication
septembre 2022
Journal
Cancer medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Pr COUTANT Charles
Tous les auteurs :
Houvenaeghel G, de Nonneville A, Chopin N, Classe JM, Mazouni C, Chauvet MP, Reyal F, Tunon de Lara C, Jouve E, Rouzier R, Daraï E, Gimbergues P, Coutant C, Azuar AS, Villet R, Crochet P, Rua S, Bannier M, Cohen M, Boher JM
Lien Pubmed
Résumé
Results of IBCSG-23-01-trial which included breast cancer patients with involved sentinel nodes (SN) by isolated-tumor-cells or micro-metastases supported the non-inferiority of completion axillary-lymph-node-dissection (cALND) omission. However, current data are considered insufficient to avoid cALND for all patients with SN-micro-metastases.
Mots clés
adjusted Kaplan-Meier estimator, axillary lymph node dissection, breast cancer, micro-metastasis, sentinel node
Référence
Cancer Med. 2022 09 20;: